Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimavanserin for Sleep in Parkinson Disease Psychosis
NCT05796167Phase 1Withdrawn
- Sponsor
- SUNY Downstate Health Sciences University
- Start
- Jan 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pimavanserin in Parkinson's disease (PD), sponsored by SUNY Downstate Health Sciences University. Primary endpoint: Effect of pimavanserin on sleep fragmentation at 6 weeks. Planned start Jan 2023; status: withdrawn.
02
Drugs
pimavanserin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05796167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05796167.